Clindamycin HCl CAS NO 21462-39-5 Inquire about Clindamycin HCl
Tecoland supplies Clindamycin HCl bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Clindamycin HCl is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.
What is Clindamycin HCl?
Clindamycin HCl is a semisynthetic lincosamide antibiotic that has largely replaced lincomycin due to an improved side effect profile. Clindamycin HCl inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits. It may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Indication of Clindamycin HCl
For the treatment of serious infections caused by susceptible anaerobic bacteria, including Bacteroides spp., Peptostreptococcus, anaerobic streptococci, Clostridium spp., and microaerophilic streptococci. May be useful in polymicrobic infections such as intra-abdominal or pelvic infections, osteomyelitis, diabetic foot ulcers, aspiration pneumonia and dental infections. May also be used to treat MSSA and respiratory infections caused by S. pneumoniae and S. pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism. May be used vaginally to treat vaginosis caused by Gardnerella vaginosa. Clindamycin reduces the toxin producing effects of S. aureus and S. pyogenes and as such, may be particularly useful for treating necrotizing fasciitis. May be used topically to treat acne.
What is the mechanism of action?
Systemic/vaginal Clindamycin inhibits protein synthesis of bacteria by binding to the 50S ribosomal subunits of the bacteria. Specifically, it binds primarily to the 23s RNA subunit. Topical Clindamycin reduces free fatty acid concentrations on the skin and suppresses the growth of Propionibacterium acnes (Corynebacterium acnes), an anaerobe found in sebaceous glands and follicles.
Pharmacodynamics of Clindamycin HCl
Clindamycin is an antibiotic, similar to and a derivative of lincomycin. Clindamycin can be used in topical or systemic treatment. It is effective as an anti-anaerobic antibiotic and antiprotozoal.
What are the side effects of Clindamycin HCl?
Adverse effects include nausea (may be dose-limiting), diarrhea, pseudomembranous colitis, allergic reactions, hepatoxicity, transient neutropenia and eosinophilia and agranulocytosis. Pseudomembranous colitis occurs in 0.01 – 10% of patients and occurs more commonly than with other antibiotics. Use of the topical formulation of Clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic Clindamycin.
How to dose Clindamycin HCl?
Adults:
Serious infections: 150 to 300 mg every 6 hours.
More severe infections: 300 to 450 mg every 6 hours.
Pediatric Patients:
Serious infections: 8 to 16 mg/kg/day (4 to 8 mg/lb/day) divided into three or four equal doses.
More severe infections: 16 to 20 mg/kg/day (8 to 10 mg/lb/day) divided into three or four equal doses.
Storage
Store the US product at room temperature between 68-77 degrees F (20-25 degrees C) away from light and moisture. Do not store in the bathroom.
Store the Canadian product at room temperature between 59-86 degrees F (15-30 degrees C) away from light and moisture. Do not store in the bathroom.
Keep all medicines away from children and pets.
Disclaimer:
Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.